

In the Claims:

1-2. (Cancelled)

3. (Currently Amended) A pharmaceutical formulation comprising an omeprazole composition fixed with a ratio of 5-methoxy and 6-methoxy isomers, wherein said ratio is determined by Fourier Transform Raman Spectroscopy and said ratio is a fixed ratio from about 5% or less of the 5-methoxy isomer and from about 95% or more of the 6-methoxy isomer.

4. (Original) The pharmaceutical formulation of claim 3, fixed with a ratio of from about 11 percent or less 5-methoxy and from about 89 percent or more 6-methoxy.

5. (Original) The pharmaceutical formulation of claim 3, fixed with a ratio of from about 17 percent or more 5-methoxy and from about 83 percent or less 6-methoxy.

6. (Previously Presented) The pharmaceutical formulation of claim 3, wherein a predetermined ratio of 5-methoxy and 6-methoxy omeprazole is selected to produce the pharmaceutical formulation.

7. (New) A pharmaceutical formulation comprising an omeprazole composition fixed with a ratio of 5-methoxy and 6-methoxy isomers, wherein said ratio is determined by Fourier Transform Raman Spectroscopy and is fixed with a ratio from about 11% or more 5-methoxy and from about 89% or less 6-methoxy.